SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced pre-clinical inflammatory arthritis ...
SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, announced that in a ...
Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of ...
A proprietary Src homology 2 (SH2) platform of integrated technologies was applied for the discovery of REX-7117 and REX-5376, two highly potent, selective and orally available SH2 domain-targeting ...
Researchers found they could disrupt STAT3's ability to act as a transcription factor by altering part of the protein, which interfered with its cancer-promoting activity. The findings suggest a basis ...
Recludix Pharma has launched with $60 million in series A funding to use DNA-encoded libraries to discover small-molecule drugs. The start-up’s focus is on inhibiting SH2 domains, protein structures ...
Researchers at the University of Helsinki, Helsinki University Central Hospital and Institute for Molecular Medicine Finland (FIMM) have discovered that a mutation in the STAT3 gene is an underlying ...
-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the interferon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results